← All trials
NCT04880746
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 17, 2020
- Primary completion
- Oct 17, 2024
- Completion date
- Oct 17, 2025
- First posted
- May 11, 2021
- Last posted
- May 11, 2021
- Enrollment
- 266
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiao Tong UniversityLead sponsor
- Anhui Medical UniversityCollaborator
- Harbin Medical UniversityCollaborator
- Fujian Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Shandong UniversityCollaborator
- Fudan UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Jiao Tong UniversityReponsible party - principal investigator
- Jiao Tong UniversityStudy chair
- Dalian Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.